Lexicon Pharmaceuticals Inc is a biopharmaceutical company dedicated to improving the lives of patients through the discovery and development of innovative medicines. The company is committed to advancing the field of drug discovery and applying its expertise to bring safe and effective therapies to patients in need. Lexicon Pharmaceuticals Inc values scientific rigor, integrity, and teamwork in its pursuit of breakthrough treatments for various diseases. With a focus on cutting-edge research and development, the company aims to make a positive impact in the healthcare industry and improve the overall quality of patient care.

Lexicon Pharmaceuticals Inc is primarily present in the United States.

Lexicon Pharmaceuticals Inc. has achieved several significant milestones in its corporate history. One noteworthy milestone is the successful FDA approval of its drug, XERMELO® (telotristat ethyl), in 2017 for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy. Another notable milestone is the collaboration agreement signed with Sanofi in 2015 to develop and commercialize sotagliflozin, an investigational medicine for diabetes. Additionally, Lexicon Pharmaceuticals Inc. has achieved positive clinical trial results for many of its pipeline products, including LX2931 for rheumatoid arthritis and sotagliflozin for type 1 diabetes. These milestones demonstrate Lexicon Pharmaceuticals Inc.'s commitment to advancing healthcare and developing innovative solutions for various medical conditions.

Lexicon Pharmaceuticals Inc. is a renowned biopharmaceutical company that specializes in the development and commercialization of innovative treatments for various diseases. Founded in 1995, Lexicon has consistently strived to improve patient lives through its breakthrough drug discovery and research programs. With a focus on therapeutic areas such as diabetes, gastrointestinal disorders, and oncology, Lexicon's extensive pipeline boasts potential novel therapies. The company has strengthened its position through strategic collaborations and partnerships with leading pharmaceutical companies. Lexicon Pharmaceuticals Inc. continues to be at the forefront of cutting-edge medical advancements, committed to delivering effective and transformative treatments for patients worldwide.

The main competitors of Lexicon Pharmaceuticals Inc in the market include pharmaceutical companies like Novartis, Pfizer, and Eli Lilly.

Lexicon Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Lexicon Pharmaceuticals Inc is centered around the development and commercialization of innovative therapies for critical medical needs. Lexicon focuses on discovering and advancing breakthrough treatments for a range of diseases, including diabetes, cancer, and neuropathic pain. The company utilizes its proprietary drug discovery and development platform to identify potential drug targets and develop novel small molecule drugs. Through collaborations and partnerships with pharmaceutical companies, Lexicon aims to bring its therapies to patients worldwide, improving their quality of life and addressing unmet medical needs.

Lexicon Pharmaceuticals KGV ir -1,35.

Lexicon Pharmaceuticals KUV ir 15,10.

AlleAktien kvalitātes vērtējums Lexicon Pharmaceuticals ir 3/10.

gaidāmā Lexicon Pharmaceuticals apgrozījums ir 24,60 milj. USD.

gaidāmā Lexicon Pharmaceuticals peļņa ir -274,84 milj. USD.

Lexicon Pharmaceuticals Inc is a pharmaceutical company founded in 1995 and based in The Woodlands, Texas, USA. The company specializes in the discovery and development of medications, particularly for the treatment of metabolic disorders such as diabetes, obesity, and hyperlipidemic conditions. Lexicon Pharmaceuticals holds a variety of patents for their medical products. Lexicon consists of two main areas: research and development, and sales and marketing. The research area is responsible for the discovery and development of new molecular therapeutics, while the sales area handles marketing activities and product sales. An important milestone for Lexicon was the discovery of the SGLT1 receptor. SGLT1 is primarily active in the intestinal mucosa and influences the absorption of food. With the help of this discovery, the medication Zynquista was developed, which reduces glucose absorption in the intestine and thereby lowers blood sugar levels. Zynquista was approved by the US Food and Drug Administration (FDA) in 2019 for the treatment of type 2 diabetes. In addition to Zynquista, Lexicon also has other medications in the pipeline that can be used for the treatment of metabolic disorders. These include the medication LX9211 for the treatment of neuropathic pain, the medication Sotagliflozin for the treatment of type 1 diabetes, and the medication LX2761 for the treatment of type 2 diabetes. In late 2021, Lexicon Pharmaceuticals entered into a partnership agreement with Sanofi to jointly sell the medication Sotagliflozin in Europe. Sanofi will be responsible for the marketing and distribution of the medication. Lexicon also operates a program called "Partners in Progress" aimed at organizations engaged in research and development in the field of metabolic disorders. Through this program, Lexicon offers a range of collaboration opportunities to advance the development of new therapies and treatment methods. Overall, Lexicon Pharmaceuticals Inc is an innovative and advanced company specializing in the discovery and development of medications for the treatment of metabolic disorders. With its research and development of new medications and collaboration with partners in the field of metabolic disorders, the company is well-positioned to continue playing an important role in the pharmaceutical industry.

Lexicon Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Lexicon Pharmaceuticals vai uzņēmums nedod dividendes.

Lexicon Pharmaceuticals ISIN ir US5288723027.

Lexicon Pharmaceuticals WKN ir A14SSK.

Lexicon Pharmaceuticals simbols ir LXRX.

Pēdējo 12 mēnešu laikā Lexicon Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Lexicon Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Lexicon Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Lexicon Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Lexicon Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Lexicon Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Lexicon Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 9.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 9.08.2024..

Pēdējās dividendes izmaksa notika 9.08.2024..

Gadā 2023, Lexicon Pharmaceuticals izmaksāja 0 USD dividendes.

Lexicon Pharmaceuticals dividendes tiek izmaksātas USD.